Detailed Information

Cited 11 time in webofscience Cited 13 time in scopus
Metadata Downloads

Sorafenib Modulates the LPS-and A beta-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice

Full metadata record
DC Field Value Language
dc.contributor.authorKim, Jieun-
dc.contributor.authorPark, Jin-Hee-
dc.contributor.authorPark, Seon Kyeong-
dc.contributor.authorHoe, Hyang-Sook-
dc.date.accessioned2023-08-16T09:31:21Z-
dc.date.available2023-08-16T09:31:21Z-
dc.date.created2022-01-11-
dc.date.issued2021-05-
dc.identifier.issn1664-3224-
dc.identifier.urihttp://scholarworks.bwise.kr/kbri/handle/2023.sw.kbri/331-
dc.description.abstractSorafenib is FDA-approved for the treatment of primary kidney or liver cancer, but its ability to inhibit many types of kinases suggests it may have potential for treating other diseases. Here, the effects of sorafenib on neuroinflammatory responses in vitro and in vivo and the underlying mechanisms were assessed. Sorafenib reduced the induction of mRNA levels of the proinflammatory cytokines COX-2 and IL-1 beta by LPS in BV2 microglial cells, but in primary astrocytes, only COX-2 mRNA levels were altered by sorafenib. Interestingly, sorafenib altered the LPS-mediated neuroinflammatory response in BV2 microglial cells by modulating AKT/P38-linked STAT3/NF-kB signaling pathways. In LPS-stimulated wild-type mice, sorafenib administration suppressed microglial/astroglial kinetics and morphological changes and COX-2 mRNA levels by decreasing AKT phosphorylation in the brain. In 5xFAD mice (an Alzheimer's disease model), sorafenib treatment daily for 3 days significantly reduced astrogliosis but not microgliosis. Thus, sorafenib may have therapeutic potential for suppressing neuroinflammatory responses in the brain.-
dc.language영어-
dc.language.isoen-
dc.publisherFRONTIERS MEDIA SA-
dc.titleSorafenib Modulates the LPS-and A beta-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice-
dc.typeArticle-
dc.contributor.affiliatedAuthorKim, Jieun-
dc.contributor.affiliatedAuthorPark, Seon Kyeong-
dc.contributor.affiliatedAuthorHoe, Hyang-Sook-
dc.identifier.doi10.3389/fimmu.2021.684344-
dc.identifier.scopusid2-s2.0-85107510701-
dc.identifier.wosid000659294300001-
dc.identifier.bibliographicCitationFRONTIERS IN IMMUNOLOGY, v.12-
dc.relation.isPartOfFRONTIERS IN IMMUNOLOGY-
dc.citation.titleFRONTIERS IN IMMUNOLOGY-
dc.citation.volume12-
dc.type.rimsART-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaImmunology-
dc.relation.journalWebOfScienceCategoryImmunology-
dc.subject.keywordPlusENDOTHELIAL GROWTH-FACTOR-
dc.subject.keywordPlusSIGNALING PATHWAYS-
dc.subject.keywordPlusPDGFR-BETA-
dc.subject.keywordPlusCROSS-TALK-
dc.subject.keywordPlusIN-VITRO-
dc.subject.keywordPlusANGIOGENESIS-
dc.subject.keywordPlusINFLAMMATION-
dc.subject.keywordPlusVEGF-
dc.subject.keywordPlusMICROGLIA-
dc.subject.keywordPlusRECEPTOR-
dc.subject.keywordAuthorLPS-
dc.subject.keywordAuthorNF-kB-
dc.subject.keywordAuthorSTAT3-
dc.subject.keywordAuthorSorafenib-
dc.subject.keywordAuthorAKT-
dc.subject.keywordAuthorMicroglia-
Files in This Item
There are no files associated with this item.
Appears in
Collections
연구본부 > 퇴행성 뇌질환 연구그룹 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Hoe, Hyang Sook photo

Hoe, Hyang Sook
연구본부 (퇴행성뇌질환 연구그룹)
Read more

Altmetrics

Total Views & Downloads

BROWSE